CRH is scheduled to report first-quarter 2026 earnings on April 30, with investors focused on revenue trends and margin performance across key regions. Consensus figures for Q1 have not been published, making management commentary on order books and pricing all the more critical.

Over the past 90 days, full-year 2026 revenue estimates have been lowered from $29.98 billion to $29.52 billion, and earnings forecasts have dipped from $4.57 to $4.52 per share. In contrast, 2027 earnings estimates were nudged up from $5.03 to $5.04 per share, reflecting cautious optimism for next year.

In the quarter ended December 31, 2025, CRH reported $15.17 billion in revenue, missing analyst expectations by 0.34%, while delivering $1.50 EPS, an 18.7% beat. The stronger earnings print drove a 1.79% share gain the following trading day.

Eleven analysts set a one-year average price target of $108.20, implying a 23.1% upside from $87.90, with a high of $145.25 and a low of $88.88. Brokerage consensus remains 'Outperform' at an average rating of 1.9, while a proprietary valuation model suggests potential downside to $82.62 over the next year.